Matthew Herper says: Adam Feuerstein at TheStreet.com is asking a pointed question about the way Wyeth and Elan are conducting a big study of their Alzheimer's drug. Why, exactly, are the companies trying to design a new way to measure Alzheimer's symptoms, and is doing so really such a good idea? |
View the Top Clips from February 29, 2008
Embed This Clip In Your Site...
|
||||||||||
|
|
|||||||||||